MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.

doi:10.1158/1078-0432.CCR-19-3321

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2020

Sato Hiroki, Schoenfeld Adam J, Siau Evan, Lu Yue Christine, Tai Huichun, Suzawa Ken, Kubota Daisuke, Lui Allan J W, Qeriqi Besnik, Mattar Marissa, Offin Michael, Sakaguchi Masakiyo, Toyooka Shinichi, Drilon Alexander, Rosen Neal X, Kris Mark G, Solit David, De Stanchina Elisa, Davare Monika A, Riely Gregory J, Ladanyi Marc, Somwar Romel

Abstract excerpt

PURPOSE: ROS1 tyrosine kinase inhibitors (TKI) provide significant benefit in lung adenocarcinoma patients with ROS1 fusions. However, as observed with all targeted therapies, resistance arises. Detecting mechanisms of acquired resistance (AR) is crucial to finding novel therapies and improve patient outcomes. EXPERIMENTAL DESIGN: ROS1 fusions were expressed in HBEC and NIH-3T3 cells either by cDNA overexpression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Oncogene Proteins, Fusion

Share to Protein-Tyrosine Kinases

Share to Survival Rate

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32122926
DOI: 10.1158/1078-0432.CCR-19-3321
PMCID: PMC8034819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.PMID 32122926Read ↗

ROS1-rearranged Non-small Cell Lung Cancer.Semantic proximity Read ↗

Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.Semantic proximity Read ↗

Discovery of oncogenic ROS1 missense mutations with sensitivity to tyrosine kinase inhibitorsSemantic proximity Read ↗

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancerSemantic proximity Read ↗

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive CancersSemantic proximity Read ↗

High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.Semantic proximity Read ↗

Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patients.Semantic proximity Read ↗

Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung CancerSemantic proximity Read ↗

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancerSemantic proximity Read ↗

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistanceSemantic proximity Read ↗

Molecular pathways: ROS1 fusion proteins in cancer.Semantic proximity Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.